Abbott Equity Method Investments decreased by 19.6% to $131.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 5.8%, from $139.00M to $131.00M. Over 5 years (FY 2020 to FY 2025), Equity Method Investments shows a downward trend with a -30.7% CAGR.
An increase indicates strategic expansion through partnerships or joint ventures, while a decrease may signal divestments or impairment.
These are investments in entities where the company exercises significant influence but does not have full control. The...
Varies significantly based on corporate strategy; common in healthcare companies that partner with biotech startups or specialized diagnostic firms.
equity_method_investments| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $805.00M | $812.00M | $816.00M | $763.00M | $82.00M | $83.00M | $169.00M | $88.00M | $95.00M | $87.00M | $141.00M | $66.00M | $65.00M | $70.00M | $139.00M | $152.00M | $158.00M | $163.00M | $131.00M |
| QoQ Change | — | +0.9% | +0.5% | -6.5% | -89.3% | +1.2% | +103.6% | -47.9% | +8.0% | -8.4% | +62.1% | -53.2% | -1.5% | +7.7% | +98.6% | +9.4% | +3.9% | +3.2% | -19.6% |
| YoY Change | — | — | — | — | -89.8% | -89.8% | -79.3% | -88.5% | +15.9% | +4.8% | -16.6% | -25.0% | -31.6% | -19.5% | -1.4% | +130.3% | +143.1% | +132.9% | -5.8% |
We use cookies for analytics. See our Privacy and Cookie Policy.